Going forward, the therapeutic management of HF in T2D should evolve from a purely hemodynamic paradigm toward strategies that integrate proven clinical benefits with targeted modulation of EAT and remodeling/inflammation biomarkers—particularly galectin-3, sST2, and GDF-15. This evidence concerns the gene LGALS3 and type 2 diabetes mellitus.